A new OMB rule from the Trump administration, "Regulation for Federal Financial Assistance," is sparking widespread concern. This rewrite of 2 CFR Part 200 grants political appointees unprecedented control over federal grantmaking, sidelining peer review. Key changes include elevating political power in funding decisions, allowing grant termination without justification, and increasing micromanagement of funds. Critics, including scientific and patient advocacy groups, warn this threatens scientific integrity, research, and innovation. The rule could impact $1.1 trillion in federal grants across all sectors, from science to education and infrastructure. The public comment period ends July 13, 2026, with calls for specific, impactful feedback. Some members of Congress also oppose the rule, fearing it will politicize grant processes and harm American innovation.
Bruce Y. Lee is a Senior Contributor at Forbes. He covers a diverse range of topics including health, medicine, wellness, and science, often focusing on consumer health, mental health, and relationships. His work has been featured in prominent publications such as MedPage Today, Psychology Today, and The Lancet.


















